Information Provided By:
Fly News Breaks for June 14, 2018
PTLA
Jun 14, 2018 | 07:16 EDT
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.
News For PTLA From the Last 2 Days
There are no results for your query PTLA